Clinical Trials Logo

Filter by:
NCT ID: NCT00913731 Completed - Clinical trials for Acute Psychotic Symptoms

Quality Project to Evaluate and Validate the FAST-O Rating Scale

FAST-O
Start date: May 2009
Phase: N/A
Study type: Observational

The purpose of this project is to test the reliability of the FAST-O Rating Scale in patients at acute wards or psychiatric intensive care units.

NCT ID: NCT00912964 Completed - Clinical trials for Urinary Bladder, Overactive

A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

CAPRICORN
Start date: April 28, 2009
Phase: Phase 3
Study type: Interventional

The study is intended to test efficacy, safety and tolerability of two doses of once daily (qd) Mirabegron against placebo to treat patients with symptoms of overactive bladder.

NCT ID: NCT00911469 Completed - Knee Osteoarthritis Clinical Trials

Study of AS902330 (rhFGF-18) Administered Intra-articularly in Patients With Knee Primary Osteoarthritis Who Are Candidates for Total Knee Replacement

Start date: November 2007
Phase: Phase 1
Study type: Interventional

Osteoarthritis (OA) is one of the most common diseases affecting the joints, usually those that are weight bearing such as the knees. OA is considered to be a disease of the cartilage in the joints even though it involves the whole joint, including the bone and synovium (thin lining of the joints which produces synovial fluid). With time, more and more of the cartilage is destroyed by the disease with inflammation commonly occurring. AS902330 is expected to increase the production and development of specific bone cells: chondrocytes and osteoblasts (cells that produce and maintain bone and cartilage). This is expected to lead to repair and regeneration of the cartilage, and a narrowing of the space width between the knee joints in a selected region of the knee.The purpose of this study is to see how safe treatment with AS902330 is, and to evaluate its effect on the knee cartilage. In addition, the study will also measure the effects of AS902330 in the blood.

NCT ID: NCT00910975 Completed - Clinical trials for Chronic Hepatitis C, Genotype 1

Individualized Duration of Peg-interferon/Ribavirin Treatment of Hepatitis C

TTG1
Start date: November 2007
Phase: Phase 4
Study type: Interventional

The purpose of the study is to investigate if the duration of treatment of hepatitis C with pegylated interferon and ribavirin can be individualized on the basis of how fast the hepatitis C virus concentration in the blood decreases, and if this is more cost-efficient than standard treatment.

NCT ID: NCT00909870 Completed - Venous Leg Ulcer Clinical Trials

Pivotal Trial of Dermagraft(R) to Treat Venous Leg Ulcers

DEVO
Start date: June 2009
Phase: Phase 3
Study type: Interventional

This study randomly assigns patients with venous leg ulcers to receive standard therapy (compression) alone or compression plus Dermagraft(R). Dermagraft is a device containing live human fibroblasts grown on an absorbable Vicryl mesh. Patients are seen weekly until they heal or the 16-week treatment period is complete. Follow-up visits are conducted monthly for three months in order to assess patients for longer term safety.

NCT ID: NCT00909129 Completed - Chronic Hepatitis C Clinical Trials

Interactions of Hepatitis C Viral (HCV) Dynamics and Immune Activation in HIV Coinfected Patients During HCV Treatment

DICO
Start date: n/a
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate T-cell mediated immune responses to HIV-1 and HCV and determine how these responses are affected by HCV treatment and correlates to response. Furthermore, to study Interferon-inducible protein-10 (IP-10) dynamics during HCV treatment, and correlate this to treatment outcome.

NCT ID: NCT00907673 Completed - Clinical trials for Congestive Heart Failure

The Automated Fluid Shunt (AFS)in Chronic Congestive Heart Failure

Start date: May 2009
Phase: N/A
Study type: Interventional

A 28-week, feasibility study to investigate the safety and efficiency of the Automatic Fluid Shunt in patients with chronic congestive heart failure, ascites and diuretic resistance.

NCT ID: NCT00907400 Completed - Healthy Clinical Trials

Phase I Study to Evaluate Bioavailability of Naproxen as PN400 Compared to Naproxen as Naprosyn E

Start date: May 2009
Phase: Phase 1
Study type: Interventional

The purpose of the study is to investigate the uptake in the body of naproxen; one of the two active substances in PN400. We also want to show that the body's uptake of naproxen given as PN400 is comparable to that of currently marketed naproxen tablets.

NCT ID: NCT00906828 Completed - Parkinson Disease Clinical Trials

Pharmacokinetics of Levodopa/Carbidopa Infusion With and Without Oral Catechol-O-methyl Transferase (COMT) Inhibitors

DuoCOMT
Start date: October 2008
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether oral intake of COMT inhibitors affects the smooth plasma levodopa levels achieved by intestinal levodopa/carbidopa infusion in advanced Parkinson's disease patients. The hypothesis is that COMT inhibitors make plasma concentrations of levodopa more fluctuating.

NCT ID: NCT00906685 Completed - Clinical trials for Central Retinal Vein Occlusion

Bevacizumab for Central Retinal Vein Occlusion Study

Start date: May 2009
Phase: Phase 3
Study type: Interventional

Central retinal vein occlusion is a leading cause of severe visual impairment. Until now, no treatment has been available to improve visual acuity. The present study intends to investigate if intravitreal bevacizumab can improve visual acuity as compared to sham-treated control patients.